High Risk Prostate Cancer clinical trials

Explore recruiting high risk prostate cancer clinical trials.

Recruiting high risk prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

High Risk Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open label, single-arm, phase 2 study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in high-risk prostate cancer patients

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Sbrt±sTad for Unfavorable iNtermediate rIsk/high-risk prostate cancer (STUNNIN): A Randomized Phase II Study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Evaluation of PSMA-PET and mpMRI in high-risk prostate cancer – using histopathologic validation

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

PSMA PET For intermediate- or high-risk prostate cancer prior to RadioTherapY: A prospective interventional randomized clinical trial (P4RTY)

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicentre Evaluation of Clinical Applications of Innovative PET/MRI with a 68Ga-PSMA-11 Radiotracer when Planning a Personalised Therapy in Prostate Cancer Patients

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

High Risk Prostate Cancer trials by city

High Risk Prostate Cancer in Toronto High Risk Prostate Cancer in Vancouver High Risk Prostate Cancer in Montreal High Risk Prostate Cancer in Calgary High Risk Prostate Cancer in Edmonton High Risk Prostate Cancer in Ottawa High Risk Prostate Cancer in Winnipeg High Risk Prostate Cancer in Quebec City High Risk Prostate Cancer in Hamilton High Risk Prostate Cancer in Kitchener High Risk Prostate Cancer in London High Risk Prostate Cancer in Halifax High Risk Prostate Cancer in New York High Risk Prostate Cancer in Los Angeles High Risk Prostate Cancer in Chicago High Risk Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease